11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome.
暂无分享,去创建一个
T. Ogata | Y. Matsubara | T. Iwasa | T. Matsuzaki | M. Irahara | Kazuki Saito | M. Fukami | M. Miyado | Tomoko Yoshida
[1] B. Keevil. Steroid Mass Spectrometry for the Diagnosis of PCOS , 2019, Medical sciences.
[2] R. Auchus,et al. Steroid biomarkers in human adrenal disease , 2019, The Journal of Steroid Biochemistry and Molecular Biology.
[3] S. Davis,et al. Exogenous Testosterone Does Not Influence 11-Oxygenated C19 Steroid Concentrations in Healthy Postmenopausal Women , 2019, Journal of the Endocrine Society.
[4] Reilly,et al. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome , 2016, The Journal of clinical endocrinology and metabolism.
[5] E. Yong,et al. Ethnic differences: Is there an Asian phenotype for polycystic ovarian syndrome? , 2016, Best practice & research. Clinical obstetrics & gynaecology.
[6] K. Storbeck,et al. 11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored , 2016, PloS one.
[7] K. Miyamoto,et al. 11-Ketotestosterone Is a Major Androgen Produced in Human Gonads. , 2016, The Journal of clinical endocrinology and metabolism.
[8] T. Giordano,et al. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. , 2016, European journal of endocrinology.
[9] T. Ogata,et al. Steroidogenic pathways involved in androgen biosynthesis in eumenorrheic women and patients with polycystic ovary syndrome , 2016, The Journal of Steroid Biochemistry and Molecular Biology.
[10] Zi-jiang Chen,et al. Local Regeneration of Cortisol by 11β-HSD1 Contributes to Insulin Resistance of the Granulosa Cells in PCOS. , 2016, The Journal of clinical endocrinology and metabolism.
[11] C. Gomez-Sanchez,et al. Development of a novel cell based androgen screening model , 2016, The Journal of Steroid Biochemistry and Molecular Biology.
[12] E. Stener-Victorin,et al. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. , 2015, Endocrine reviews.
[13] S. Sirmans,et al. Epidemiology, diagnosis, and management of polycystic ovary syndrome , 2013, Clinical epidemiology.
[14] P. Swart,et al. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: A putative role in castration resistant prostate cancer? , 2013, Molecular and Cellular Endocrinology.
[15] Yasuhiro Nakamura,et al. Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. , 2013, The Journal of clinical endocrinology and metabolism.
[16] A. Zhao,et al. The expression of sex steroid synthesis and inactivation enzymes in subcutaneous adipose tissue of PCOS patients , 2012, The Journal of Steroid Biochemistry and Molecular Biology.
[17] Ricardo Azziz,et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis , 2011, Nature Reviews Endocrinology.
[18] P. Ferrari. The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension. , 2010, Biochimica et biophysica acta.
[19] E. Maser,et al. 11β-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation , 2010, The Journal of Steroid Biochemistry and Molecular Biology.
[20] G. S. Cowan,et al. Hepatic Gene Expression in Morbidly Obese Women: Implications for Disease Susceptibility , 2009, Obesity.
[21] R. Norman,et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. , 2009, Fertility and sterility.
[22] Richard S Legro,et al. Polycystic ovary syndrome , 2007, The Lancet.
[23] R. Norman,et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. , 2006, The Journal of clinical endocrinology and metabolism.
[24] D. Dewailly,et al. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. , 2006, The Journal of clinical endocrinology and metabolism.
[25] F. Stanczyk. Diagnosis of hyperandrogenism: biochemical criteria. , 2006, Best practice & research. Clinical endocrinology & metabolism.
[26] R. Azziz. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. , 2006, The Journal of clinical endocrinology and metabolism.
[27] C. Galletly,et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. , 1995, Human reproduction.
[28] C. Edwards,et al. 5 α-reductase activity in polycystic ovary syndrome , 1990, The Lancet.
[29] Enrico Carmina,et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. , 2012, Fertility and sterility.